{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T13:40:18Z","timestamp":1711201218149},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T00:00:00Z","timestamp":1264550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12032-010-9425-3","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T14:23:49Z","timestamp":1264515829000},"page":"219-230","source":"Crossref","is-referenced-by-count":9,"title":["WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval"],"prefix":"10.1007","volume":"28","author":[{"given":"Anri","family":"Saitoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwako","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Tochiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akie","family":"Yamahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Masuko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Toba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifusa","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,27]]},"reference":[{"key":"9425_CR1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1586\/14760584.7.7.1041","volume":"7","author":"M Dauer","year":"2008","unstructured":"Dauer M, Schnurr M, Eigler A. Dendritic cell-based cancer vaccination: quo vadis? Expert Rev Vaccines. 2008;7:1041\u201353.","journal-title":"Expert Rev Vaccines"},{"key":"9425_CR2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.coi.2008.04.009","volume":"20","author":"Y Oka","year":"2008","unstructured":"Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008;20:211\u201320.","journal-title":"Curr Opin Immunol"},{"key":"9425_CR3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/156652409788970670","volume":"9","author":"U Petrausch","year":"2009","unstructured":"Petrausch U, et al. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med. 2009;9:673\u201382.","journal-title":"Curr Mol Med"},{"key":"9425_CR4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2008.01.011","volume":"28","author":"N Demotte","year":"2008","unstructured":"Demotte N, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 2008;28:414\u201324.","journal-title":"Immunity"},{"key":"9425_CR5","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2174\/092986706777935104","volume":"13","author":"Y Oka","year":"2006","unstructured":"Oka Y, et al. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem. 2006;13:2345\u201352.","journal-title":"Curr Med Chem"},{"key":"9425_CR6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3171\/JNS\/2008\/108\/5\/0963","volume":"108","author":"S Izumoto","year":"2008","unstructured":"Izumoto S, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108:963\u201371.","journal-title":"J Neurosurg"},{"key":"9425_CR7","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","volume":"101","author":"Y Oka","year":"2004","unstructured":"Oka Y, et al. Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9425_CR8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1348-0421.2004.tb03503.x","volume":"48","author":"A Tsuboi","year":"2004","unstructured":"Tsuboi A, et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol. 2004;48:175\u201384.","journal-title":"Microbiol Immunol"},{"key":"9425_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1348-0421.2007.tb03940.x","volume":"51","author":"T Iiyama","year":"2007","unstructured":"Iiyama T, et al. WT1 (Wilms\u2019 tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol. 2007;51:519\u201330.","journal-title":"Microbiol Immunol"},{"key":"9425_CR10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08880010802435500","volume":"26","author":"H Ohta","year":"2009","unstructured":"Ohta H, et al. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol. 2009;26:74\u201383.","journal-title":"Pediatr Hematol Oncol"},{"key":"9425_CR11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.21387","volume":"84","author":"M Yasukawa","year":"2009","unstructured":"Yasukawa M, et al. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome. Am J Hematol. 2009;84:314\u20135.","journal-title":"Am J Hematol"},{"key":"9425_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.leu.2403186","volume":"18","author":"V Mailander","year":"2004","unstructured":"Mailander V, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165\u20136.","journal-title":"Leukemia"},{"key":"9425_CR13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236\u201342.","journal-title":"Blood"},{"key":"9425_CR14","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541\u20138.","journal-title":"Blood"},{"key":"9425_CR15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1532\/IJH97.06194","volume":"85","author":"M Kawakami","year":"2007","unstructured":"Kawakami M, et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg\/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol. 2007;85:426\u20139.","journal-title":"Int J Hematol"},{"key":"9425_CR16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02983998","volume":"86","author":"A Tsuboi","year":"2007","unstructured":"Tsuboi A, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86:414\u20137.","journal-title":"Int J Hematol"},{"key":"9425_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF02983241","volume":"78","author":"Y Oka","year":"2003","unstructured":"Oka Y, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78:56\u201361.","journal-title":"Int J Hematol"},{"key":"9425_CR18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","volume":"51","author":"A Tsuboi","year":"2002","unstructured":"Tsuboi A, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother. 2002;51:614\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"9425_CR19","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.4049\/jimmunol.171.9.4898","volume":"171","author":"V Karanikas","year":"2003","unstructured":"Karanikas V, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol. 2003;171:4898\u2013904.","journal-title":"J Immunol"},{"key":"9425_CR20","first-page":"171","volume":"8","author":"T Furukawa","year":"1994","unstructured":"Furukawa T, et al. Establishment of a new cell line with the characteristics of a multipotential progenitor from a patient with chronic myelogenous leukemia in early erythroblastic crisis. Leukemia. 1994;8:171\u201380.","journal-title":"Leukemia"},{"key":"9425_CR21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804\u201311.","journal-title":"Blood"},{"key":"9425_CR22","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","volume":"115","author":"J Dannull","year":"2005","unstructured":"Dannull J, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623\u201333.","journal-title":"J Clin Invest"},{"key":"9425_CR23","first-page":"606","volume":"9","author":"AM Wolf","year":"2003","unstructured":"Wolf AM, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606\u201312.","journal-title":"Clin Cancer Res"},{"key":"9425_CR24","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","volume":"27","author":"A Merlo","year":"2009","unstructured":"Merlo A, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27:1746\u201352.","journal-title":"J Clin Oncol"},{"key":"9425_CR25","doi-asserted-by":"crossref","unstructured":"Chappert P, et al. Antigen-specific Tregs impair CD8 T cell priming by blocking early T cell expansion. Eur J Immunol. 2009.","DOI":"10.1002\/eji.200839107"},{"key":"9425_CR26","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/1521-4141(200206)32:6<1688::AID-IMMU1688>3.0.CO;2-9","volume":"32","author":"N Demotte","year":"2002","unstructured":"Demotte N, et al. A reversible functional defect of CD8\u00a0+\u00a0T lymphocytes involving loss of tetramer labeling. Eur J Immunol. 2002;32:1688\u201397.","journal-title":"Eur J Immunol"},{"key":"9425_CR27","doi-asserted-by":"crossref","first-page":"32878","DOI":"10.1074\/jbc.273.49.32878","volume":"273","author":"RS Lin","year":"1998","unstructured":"Lin RS, Rodriguez C, Veillette A, Lodish HF. Zinc is essential for binding of p56(lck) to CD4 and CD8alpha. J Biol Chem. 1998;273:32878\u201382.","journal-title":"J Biol Chem"},{"key":"9425_CR28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2008.09.014","volume":"340","author":"A Lissina","year":"2009","unstructured":"Lissina A, et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods. 2009;340:11\u201324.","journal-title":"J Immunol Methods"},{"key":"9425_CR29","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.4049\/jimmunol.173.12.7200","volume":"173","author":"R Morgan","year":"2004","unstructured":"Morgan R, et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J Immunol. 2004;173:7200\u20138.","journal-title":"J Immunol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9425-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9425-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:22:43Z","timestamp":1559427763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["9425"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9425-3","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,27]]}}}